Diagnostics developer HealthLinx Limited (HTX) will open its second market for its highly accurate ovarian cancer diagnostic OvPlexTM. United Kingdom Distributor Intus Healthcare has completed a commercial arrangement with major hospital and healthcare services group Spire Healthcare to process and market OvPlexTM in the UK from February 2010. The market potential for OvPlexTM in the UK is greater than 750,000 units. OvPlexTM is the most accurate commercially-available ovarian cancer diagnostic. The diagnostic is based on a simple blood test that women can request from their doctors. The launch in the UK is the first time the OvPlexTM diagnostic will be available outside Australia.
“This is the next step in the global roll-out of OvPlexTM and we are confident that OvPlexTM is a best in market ovarian cancer diagnostic, as are our distribution partners. The company continues to deliver on its milestones and we believe commercial markets will respond positively to this latest achievement” says Mr Nick Gatsios, Managing Director of HealthLinx.
Spire Healthcare is the second largest private hospital group in the UK, with a network of 36 hospitals nationwide. The group offers a range of services including pathology, diagnostic tests and investigations as well as the latest surgical procedures. The OvPlexTM test will be made available through its hospitals throughout England, Scotland and Wales. HealthLinx Limited (HTX) uses biomarkers to develop best practice diagnostics that detect and monitor diseases. Intus Healthcare is a specialist healthcare company focussed on the private sector and are authorised resellers or distributors for many multi-national corporations including Sunrise Medical Inc., SomnoMed Limited (SOM), Cardinal Health, Fisher & Paykel etc.
Tags: Distribution Agreement, Healthcare, Healthlinx, HTX
